Michael joined Brandon Capital in 2016.
Before joining, Michael was a Senior Business Development Manager at Monash University where he managed the Life Science portfolio for the Faculty of Medicine. Prior to this, he was an Investment Manager (Life Sciences) at the TTCF, a seed/venture commercialisation fund manager focused on opportunities derived from academic research. Michael has led due diligence and deal negotiations on numerous Life Science transactions and investee companies, including Nexvet (NVET – NASDAQ: acquired by Zoetis in 2017). Michael’s research experience includes a Roche Research Foundation post-doctoral fellowship at the ISREC (EPFL) in Lausanne, Switzerland.
Michael is currently a director of; Cincera Therapeutics, Foray Therapeutics, and Currus Biologics.
Michael has a Bachelor of Science (Honours) from the University of Adelaide, a PhD in stem cell biology from the University of Adelaide and an MBA specialising in technology management from LaTrobe University. Michael is also a graduate of the Australian Institute of Company Directors (AICD).